Login
REGENXBIO NASDAQ: RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
| Name | REGENXBIO |
| Ticker | RGNX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
|
Price
52W Low/High |
35.44
26.52 / 49.95 |
| Momentum | Neutral |
| Market cap | 1.5 B |
| 1Y Total Return |
-7.44%
Weak |
| 1Y Volatility |
52.92%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects
Details
| Ticker | RGNX |
| Name | REGENXBIO |
| ISIN | US75901B1070 |
| CUSIP | 75901B107 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 5/18/21
| Close Price | 35.44 |
| 52W Low/High | 26.52 / 49.95 |
| Market cap | 1.5 B |
| 1Y Total Return |
-7.44%
Weak |
| 1Y Volatility |
52.92%
More Risk |
| Beta | 3.14 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -77.9% |
| Cash from Op. / Cur. Liabilities | -0.71 |
| Diluted Earnings / Share | -3.11 |
| ROE | - |
| ROIC | -26.4% |
| Price / Revenue | 9.5 |
| Price / Book | 2.7 |
| Price / CF | -24.9 |
| Current Ratio | 5.9 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.14 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
156
|
52
|
87
|
142
|
5
|
7
|
|
| Gross Profit |
119
|
40
|
80
|
138
|
4
|
6
|
|
| R&D |
169
|
136
|
90
|
60
|
56
|
21
|
|
| EBITDA |
-100
|
-98
|
-28
|
56
|
-74
|
-29
|
|
| Operating Income |
-126
|
-151
|
-50
|
49
|
-77
|
-30
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
53
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
42
|
37
|
36
|
34
|
27
|
26
|
|
| EPS exc. Extra |
-3.11
|
-2.78
|
-1.09
|
1.39
|
-2.80
|
-2.28
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
879
|
464
|
519
|
317
|
224
|
215
|
|
| Cash, Eq & Invt ShortTerm |
442
|
281
|
286
|
230
|
146
|
101
|
|
| Total Current Assets |
499
|
338
|
304
|
263
|
149
|
106
|
|
| Total Non-Current Assets |
381
|
126
|
215
|
54
|
75
|
109
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
325
|
44
|
32
|
18
|
11
|
6
|
|
| Total Current Liabilities |
84
|
32
|
21
|
15
|
10
|
6
|
|
| Long Term Debt |
241
|
12
|
11
|
3
|
1
|
1
|
|
| Shareholder equity |
555
|
420
|
487
|
299
|
213
|
209
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-60
|
-114
|
17
|
18
|
-58
|
-29
|
|
| Depreciation |
8
|
8
|
5
|
3
|
1
|
0
|
|
| Cash from Investing |
-124
|
121
|
-237
|
-45
|
33
|
-174
|
|
| Capex |
53
|
14
|
13
|
7
|
11
|
1
|
|
| Cash from Financing |
406
|
7
|
204
|
17
|
72
|
213
|
|
| Stock Issued |
223
|
7
|
205
|
18
|
72
|
145
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-62
|
-84
|
-223
|
32
|
-75
|
-
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
37.3%
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
35.9%
|
-
|
-
|
|
| Current Ratio |
5.9
|
10.6
|
14.2
|
17.7
|
14.9
|
18.3
|
|
| Financial Leverage D/E |
0.14
|
0.02
|
0.02
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-26.4%
|
-24.1%
|
-8.9%
|
29.3%
|
-48.1%
|
-34.0%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
20.7%
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available